Skip to main content

AVITA Medical, Inc.

corporate_fare Company Profile

AVITA Medical, Inc.

RCEL·NASDAQ·Life Sciences·CIK 0001762303

AVITA Medical is a therapeutic acute wound care company that provides solutions for wound healing. The company's technologies address healing needs from burns, traumatic injuries, and surgical repairs through a portfolio of proprietary and complementary products. These products support wound bed preparation, definitive closure, and recovery. The current commercial portfolio includes RECELL, PermeaDerm, and Cohealyx. RECELL is approved by the United States Food & Drug Administration (FDA) for treating thermal burn wounds and full-thickness skin defects. While RECELL is also approved in the United States for restoring pigmentation of stable depigmented vitiligo lesions, the company has paused further commercial investment in vitiligo. In January 2024, AVITA Medical entered an exclusive multi-year distribution agreement with Stedical Scientific, Inc. to market, sell, and distribute PermeaDerm, a biosynthetic wound matrix, in the U.S. In March 2025, the company also entered a multi-year agreement to manufacture PermeaDerm. In July 2024, AVITA Medical entered an exclusive multi-year development and distribution agreement with Collagen Matrix, LLC d/b/a as Regenity Biosciences, granting exclusive rights to market, sell, and distribute Cohealyx, an AVITA-medical branded collagen-based dermal matrix, in the U.S., with potential expansion into the E.U., Australia, and Japan. Cohealyx was commercially launched in the U.S. on April 1, 2025. AVITA Medical Limited, the former Australian parent company, was founded in December 1992. On October 1, 2019, AVITA Australia began trading its American Depositary Shares on the Nasdaq Capital Market under the symbol "RCEL". In 2020, the Company redomiciled to the U.S.

AVITA Medical, Inc. (NASDAQ:RCEL) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 24 items for RCEL at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • AVITA Medical Reports Full-Year 2025 Results with Going Concern Warning, Details Debt Refinancing & Equity Raise
  • AVITA Medical Reports Mixed Q4, Strong Full-Year 2025 Results, Guides for 12-19% Revenue Growth in 2026
  • AVITA Medical Secures $60M Senior Secured Credit Facility, Refinances Debt, and Issues Warrants
  • AVITA Medical Appoints Seasoned Healthcare Executive Joe Woody to Board of Directors

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$71.61M
Net Income
-$48.59M
Diluted EPS
-$1.74
Op. Cash Flow
-$31.2M
Free Cash Flow
-$32.2M
Gross Profit
$58.82M
Operating Income
-$42.53M
Cash & Equivalents
$10.24M
Total Debt
$42.98M
Debt / Equity
-2.58×
Net Margin
-67.8%
Shares Outstanding
30.57M sh
Source: 10-K · filed 2026-02-12 · accession 0001193125-26-049031
$15.31 -1.98% today
52-week range · as of 2026-11-05 $3.22 – $16.9
Market cap
$490.78M
Volume
387K (0.7× avg)
3-mo avg 542.2K
Live data · 2026-11-22 12:34 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed RCEL - Filings & News (Page 2)

RCEL
Feb 12, 2026, 5:20 PM EST
Filing Type: 10-K
Importance Score:
9
Price at Filing: $3.54
Real-time Price: $15.31 info
Change: +$11.77 (+332%) info
Market Cap: $490.784M info
RCEL
Feb 12, 2026, 4:15 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.50
Real-time Price: $15.31 info
Change: +$11.81 (+337%) info
Market Cap: $490.784M info
RCEL
Jan 13, 2026, 8:30 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.60
Real-time Price: $15.31 info
Change: +$11.71 (+325%) info
Market Cap: $490.784M info
RCEL
Jan 05, 2026, 4:11 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.47
Real-time Price: $15.31 info
Change: +$11.84 (+341%) info
Market Cap: $490.784M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets